Get the Stockscreener App
0.5746
4.79%
-0.0289
After Hours:
.58
0.0054
+0.94%
Werewolf Therapeutics Inc stock is traded at $0.5746, with a volume of 1.05M.
It is down -4.79% in the last 24 hours and down -47.76% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
See More
Previous Close:
$0.6035
Open:
$0.6045
24h Volume:
1.05M
Relative Volume:
1.22
Market Cap:
$27.89M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-0.5525
EPS:
-1.04
Net Cash Flow:
$-33.38M
1W Performance:
-10.83%
1M Performance:
-47.76%
6M Performance:
-51.71%
1Y Performance:
-58.36%
1-Day Range:
$0.56
$0.6084
1-Week Range:
$0.56
$0.67
52-Week Range:
$0.5588
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
0.5746 | 29.29M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.59 | 117.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.00 | 83.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
796.00 | 48.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.91 | 52.62B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
333.99 | 37.39B | 4.98B | 69.59M | 525.67M | 0.5197 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Evnin Luke sells Werewolf Therapeutics (HOWL) shares for $53,533 - Investing.com
Evnin Luke sells Werewolf Therapeutics (HOWL) shares for $53,533 By Investing.com - Investing.com Australia
Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results - Finviz
Risk Analysis: Will Werewolf Therapeutics Inc. stock benefit from infrastructure spending2025 Technical Patterns & Daily Growth Stock Tips - ulpravda.ru
Is Werewolf Therapeutics Inc. stock ready for breakout2025 Growth vs Value & High Win Rate Trade Tips - ulpravda.ru
Werewolf Therapeutics (HOWL) upgraded to buy: Here's what you should know - MSN
Aug Analyst Calls: Can Werewolf Therapeutics Inc. stock hit analyst price targetsPortfolio Value Summary & Verified Technical Trade Signals - ulpravda.ru
How rising interest rates impact Werewolf Therapeutics Inc. stockJuly 2025 Opening Moves & Technical Analysis for Trade Confirmation - ulpravda.ru
Evnin Luke sells Werewolf Therapeutics (HOWL) stock for $45,882 - Investing.com
Evnin Luke sells Werewolf Therapeutics (HOWL) stock for $45,882 By Investing.com - Investing.com India
Luke Evnin Sells 34,847 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - Defense World
HOWL Stock Price, Forecast & Analysis | WEREWOLF THERAPEUTICS INC (NASDAQ:HOWL) - Chartmill
Will Werewolf Therapeutics Inc. stock return to pre crisis levelsAnalyst Upgrades & Capital Efficiency Improvement - bollywoodhelpline.com
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Consensus Rating of “Hold” from Analysts - Defense World
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Werewolf Therapeutics (HOWL) - The Globe and Mail
Market Moves: Is Werewolf Therapeutics Inc. stock ready for breakoutWeekly Trade Summary & Real-Time Stock Price Movement Reports - moha.gov.vn
Will Werewolf Therapeutics Inc. stock benefit from infrastructure spendingProduct Launch & Free Accurate Trade Setup Notifications - Улправда
Werewolf Therapeutics (NASDAQ:HOWL) Downgraded to “Neutral” Rating by Wedbush - Defense World
Why retail investors pile into Werewolf Therapeutics Inc. stockRisk Management & Technical Confirmation Trade Alerts - Улправда
HC Wainwright & Co. Maintains Werewolf Therapeutics (HOWL) Buy Recommendation - Nasdaq
H.C. Wainwright slashes Werewolf Therapeutics stock price target on pipeline update By Investing.com - Investing.com Nigeria
Can Werewolf Therapeutics Inc. stock hit analyst price targetsOil Prices & Capital Protection Trading Alerts - DonanımHaber
Wedbush Downgrades Werewolf Therapeutics to Neutral From Outperform Due to 'Forward Challenging' Path, Cuts Price Target to $1 From $3 - marketscreener.com
H.C. Wainwright slashes Werewolf Therapeutics stock price target on pipeline update - Investing.com Nigeria
Werewolf Therapeutics advances Inducer platform candidates - BioWorld MedTech
Werewolf Therapeutics Announces Pipeline and Business Updates - Investing News Network
Werewolf Therapeutics Updates Pipeline and Outlines 2026 Priorities - TipRanks
Werewolf Therapeutics Incplans for two INDs by mid-2027 - marketscreener.com
Werewolf Therapeutics, Inc. Announces Pipeline Update and 2026 Priorities - TradingView — Track All Markets
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 14,548 Shares of Stock - MarketBeat
Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 9,983 Shares of Stock - MarketBeat
[Form 4] Werewolf Therapeutics, Inc. Insider Trading Activity - Stock Titan
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why - MSN
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know - sharewise.com
What analysts say about Werewolf Therapeutics Inc stockInsider Trading Activity & Free Superior Stock Performance - earlytimes.in
Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 17,858 Shares - MarketBeat
Luke Evnin Sells 37,104 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $29,969.63 in Stock - MarketBeat
Werewolf Therapeutics, Inc. (HOWL) director discloses Rule 10b5-1 stock sales - Stock Titan
IPO Launch: What is the fair value of Werewolf Therapeutics Inc stock nowWeekly Investment Report & Momentum Based Trading Signals - moha.gov.vn
How Werewolf Therapeutics Inc. stock benefits from global expansionEarnings Summary Report & Expert Curated Trade Setup Alerts - Newser
What is the fair value of Werewolf Therapeutics Inc. stock nowStop Loss & Daily Profit Maximizing Tips - Newser
Werewolf Therapeutics (HOWL) former 10% owners sell $183k in stock - Investing.com India
MPM BioVentures sells Werewolf Therapeutics (HOWL) stock for $183k - Investing.com India
MPM BioVentures sells Werewolf Therapeutics (HOWL) stock for $183k By Investing.com - Investing.com Australia
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
2.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):